anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
DD mg (final doses will be selected based upon data obtained in the single dose sessions (i.e., Sessions I, II, and III) TMC589354 (n=6) b.i.d. during 7 days (Session VIb) ) plus a single oral dose of 300 mg of TMC310911 on Day 7. After at least 14 days following Day 7 of multiple dosing, participants will receive 300 mg TMC310911, single dose (Session IXb).
BACKGROUND: Glioma stem cells (GSCs) are the root cause of relapse and treatment resistance in glioblastoma (GBM). In GSCs, hypoxia in the microenvironment is known to facilitate the maintenance of stem cells, and evolutionally conserved autophagy regulates cell homeostasis to control cell population. The precise involvement of autophagy regulation in hypoxic conditions in maintaining the stemness of GSCs remains unclear.
METHODS: The association of autophagy regulation and hypoxia was first assessed by in silico analysis and validation in vitro. Glioma databases and clinical specimens were used to determine galectin-8 (Gal-8) expression in GSCs and human GBMs, and the regulation and function of Gal-8 in stemness maintenance were evaluated by genetic manipulation in vitro and in vivo. How autophagy was stimulated by Gal-8 under hypoxia was systematically investigated.
RESULTS: Hypoxia enhances autophagy in GSCs to facilitate self-renewal, and Gal-8 in the galectin family is specifically involved and expressed in GSCs within the hypoxic niche. Gal-8 is highly expressed in GBM and predicts poor survival in patients. Suppression of Gal-8 prevents tumor growth and prolongs survival in mouse models of GBM. Gal-8 binds to the Ragulator-Rag complex at the lysosome membrane and inactivates mTORC1, leading to the nuclear translocation of downstream TFEB and initiation of autophagic lysosomal biogenesis. Consequently, the survival and proliferative activity of GSCs are maintained.
CONCLUSIONS: Our findings reveal a novel Gal-8-mTOR-TFEB axis induced by hypoxia in the maintenance of GSC stemness via autophagy reinforcement, highlighting Gal-8 as a candidate for GSCs-targeted GBM therapy.
The invention provides an acne and speckle eliminating drug and a preparation method thereof. The drug is made of traditional Chinese herbals, can be applied on the affected parts externally, has a good pain-relieving effect, and is very convenient to use. The drug can be smeared on the skin to moisten the skin, is capable of maintaining the optimal state of skin tissues of wounds, and promotes the self-repairing process of skin. Furthermore, the drug cuts off the contact between the bacteria in the air and the skin, and thus reduces the possibility of infection. The drug is nonirritant and stable, is not easy to degrade, will not cause allergy, and is especially suitable for people who are allergic to cosmetic additives such as essences, alcohol, and the like. The drug contains tea seed oil, which contains vitamin E and antioxidant components, so the drug can protect skin, prevent skin damage and aging, and make skin smooth and bright, and moreover, the drug can treat chloasma and sunburn.
A planktonic concept of the bacteria present on the surface of a chronic wound is no longer viable. Microscopic studies show that biofilm is present on chronic wounds yet does not seem to be prominent on the surface of acute wounds. Biofilm is able to neutralize our host defenses and commandeer host systems, and possesses an impressive array of defenses and virulence factors. Clinically we see a significant difference in the healing behavior between chronic and acute wounds. Also, suppression of biofilm using multiple simultaneous strategies including debridement, anti-biofilm agents, specific biocides, antibiotics and advanced technologies improves wound healing. This suggests biofilm plays an important role in delayed wound healing.
Cardiovascular disease remains the most common cause of death in Ireland. Usage of antiplatelet agents and cardiac procedures such as coronary angioplasty has dramatically improved the morbidity and mortality associated with coronary artery disease. In patients with a coronary stent, dual antiplatelet therapy is recommended. Aspirin is the main antiplatelet agent used. For many years, clopidogrel was the second antiplatelet of choice. Recent studies have revealed new antiplatelet drugs that can substitute clopidogrel, one of which is ticagrelor. Ticagrelor received approval from regulatory authorities such as the Food and Drug Administration and the European Medicines Agency based on the PLATO trial which demonstrated a reduction in overall mortality and thrombotic cardiovascular events when compared to clopidogrel. Ticagrelor is approved in Europe and specifically in Ireland for use in patients with ACS and in patients undergoing coronary angioplasty. The degree to which ticagrelor reduced the overall mortality compared to clopidogrel in the PLATO trial suggested that ticagrelor possibly has a pleiotropic effect and that the reduction in mortality is not simply due to its antiplatelet effects. The ticagrelor molecule resembles adenosine. It has been shown that ticagrelor increases adenosine concentration, by interfering with its red blood cells' uptake and by inducing the release of ATP which is then converted to adenosine. Adenosine has been shown to be cardioprotective.

Peripheral Arterial Tonometry (EndoPAT 2000 system (Itamar Medical, Caesarea, Israel) is a method for evaluating endothelial dysfunction. The device has received a CE mark (approved for use in Europe). It uses a non-invasive assessment called fingertip pulse amplitude tonometry.

The reactive hyperaemia response as detected by the reactive hyperaemia index (RHI) has been shown to be related to multiple traditional and metabolic risk factors. It has also been found to positively correlate with flow mediated dilatation (FMD) and coronary vasoreactivity as assessed by intracoronary acetylcholine. A significant advantage of the endoPAT device is the reproducibility of results when compared to FMD in assessment of peripheral endothelial function. Smaller studies have shown positive effects of ticagrelor on endothelial function assessment compared with clopidogrel or prasugrel but no randomised study has been done to date.

The aim of this project is to study the effects of ticagrelor on the arterial system using a noninvasive method. The study will employ the measurement of peripheral endothelial function of patients who undergo percutaneous coronary intervention who are on ticagrelor vs. clopidogrel using a cross over trial design.
FIELD: medicine. SUBSTANCE: method involves daily irrigating the wound with 20-% aqueous Mefopran solution at the first stage of wound process development. Electromagnetic extremely high frequency field is applied to biologically active points with hair cut in advance at the first and the second stage of wound process development. The first point is placed below the superior edge of lateral tibial condyle near the anterior boundary of the tibial muscle. The second point is placed in the area of the hip joint. The third one is placed in popliteal area, the fourth one is above the superior edge of the kneepan, the fifth one is on the lateral surface of the knee joint behind the lateral femoral epicondyle. 20-% Mefopran emulsion prepared with castor oil is applied in every day mode to the wound at the second stage of wound process development. The number of irradiation treatments at the first and the second stages is brought in total to 10-12 treatments. Another version of treatment method involves exposing wound surface with electromagnetic extremely high frequency field during 10-20 min at the first and the second stages. The exposure being over, the wound is daily irrigated with the 20% aqueous Mefopran solution, and applying 20% Mefopran emulsion prepared with castor oil at the second stage. The number of irradiation treatments at the first and the second stages is brought in total to 10-12 treatments. EFFECT: enhanced effectiveness of treatment course; accelerated recovery of wounded dogs. 2 cl, 1 dwg
In a double-blind, placebo-controlled study of 32 patients of both sexes, aged 32 to 69 years, with stable angina, propranolol 100 mg t.i.d. was administered for 4 weeks and shown to be more effective than placebo in reducing the rate of angina episodes and in prolonging total exercise time.

Twelve male patients with moderately severe angina pectoris were studied in a double-blind, crossover study. Patients were randomized to either Inderal LA 160 mg daily or conventional propranolol 40 mg four times a day for 2 weeks. Nitroglycerine tablets were allowed during the study. Blood pressure, heart rate and ECG's were recorded during serial exercise treadmill testing. Inderal LA was as effective as conventional propranolol for exercise heart rate, systolic and diastolic blood pressure, duration of anginal pain and ST-segment depression before or after exercise, exercise duration, angina attack rate and nitroglycerine consumption.

In another double-blind, randomized, crossover trial, the effectiveness of Inderal LA 160 mg daily and conventional propranolol 40 mg four times a day were evaluated in 13 patients with angina. ECG's were recorded while patients exercised until angina developed. Inderal LA was as effective as conventional propranolol for amount of exercise performed, ST-segment depression, number of anginal attacks, amount of nitroglycerine consumed, systolic and diastolic blood pressures and heart rate at rest and after exercise.
Drugs that inhibit the renin-angiotensin system can cause hyperkalemia.

Concomitant use of candesartan cilexetil with drugs that increase potassium levels may increase the risk of hyperkalemia [see Drug Interactions (7.1)].

Monitor serum potassium periodically.

In the CHARM program (heart failure patients), the incidence of hyperkalemia was 6.3% in patients treated with candesartan cilexetil versus 2.1% in patients treated with placebo. The incidence of hyperkalemia leading to drug discontinuation in candesartan cilexetil-treated patients was 2.4% compared with 0.6% in placebo-treated patients. In the CHARM-Added program where candesartan or placebo was given in addition to ACE inhibitors, the incidence of hyperkalemia was 9.5% in patients treated with candesartan cilexetil versus 3.5% in patients treated with placebo [see Drug Interactions (7.1)].
PROBLEM TO BE SOLVED: To eliminate the permeation-diffusion of a drug and to make an expansion/contraction property improve by laminating at least one kind of film out of a fluororubber and a fluoroelastomer on soft films each of which has a specified thickness. SOLUTION: This support for a dermal administration drug is constituted by a method in which a film 1-100μm thick which is made from at least one kind out of a fluororubber and a fluoroelastomer is laminated on a soft film 10-200μm thick. As the soft film, a styrene elastomer and a polyolefin elastomer are preferable because of their good expansion/contraction property. As the fluororubber, in consideration of the processing method of lamination on the soft film by gravure coater, etc., a liquid fluororubber and a fluororubber soluble in an organic solvent are preferable. As the liquid fluororubber, propylene-tetra fluoroethylene copolymerization liquid rubber, etc., are named. As the fluororubber soluble in an organic solvent, vinylidene fluoride-haxa fluoropropylene-tetra fluoroethylene ternary copolymerivation rubber, etc., are named.
Participants who will receive gonadotoxic chemoradiation therapies to include the alkylating agents, heavy metals and plant alkaloids as a standard part of their cancer treatment. Participants will also receive the GnRHa for menstrual suppression as part of standard of care. Baseline blood draws and pelvic ultrasound will be the intervention. Repeat blood draws and pelvic ultrasound at 6 and 12 months will also be interventions.
Administration is carried out by spraying into the teats of the mammary gland, or the uterus or vagina of the ruminant, the therapeutic agent in an excipient which will form a foam having 20 to 20 times the volume of formulations conventionally administered by syringe or flexible tube.. The formation is sepcif. prepared by forming an oil-water emulsion contg. the therapeutic agent, and filling this into an aerosol container, which is pressurised by a mixt of CCL2F2 and butane. The proportions of the propellant gas are adjusted to give it the same density as the emulsion, and the preferred proportions are 55% of CCl2F2 and 45% of butane. When the compn is administered, the propellant gas immediately expands to form a foam consisting of minute bubbles, which penetrates the treatment site completely. The compn does not give rise to a sensation of cold when used.
FIELD: pharmacy. SUBSTANCE: invention relates to preparing coptisin from the ground part of plant celandine (Chelidonium majus L.). Method involves multistep extraction with chloroorganic solvent in alkaline medium, reextraction with sulfuric acid an aqueous solution followed by feeding an aqueous phase to filtration, washing and drying the end product. Chloroform is used as a solvent and extraction is carried out by 12 steps (each step - 20 min) at stirring and at ratio herb mass and solvent volume solid : liquid = 1: 10. For reextraction 1/2 reaction volume of solvent from each step is fed at ratio of an aqueous and organic phase volumes = 1:1.5 and reextraction is carried out for 15 min at intensive stirring. After coptisin crystals filtration mother liquor is recovered to reextraction stage and ratio of phases solid : liquid = 1:10 is maintained at extraction stage by recovery of organic phase from reextraction stage. EFFECT: increased yield, simplified process, decreased consumption of reagent, improved safety. 1 tbl
An electromagnetic field generating apparatus for treating pathological cells, in particular with tumor suppression function. The ratio of static magnetic field to alternating magnetic field is in the range of 0.5-2.5, and the total intensity is in the range up to 100 mT. It provides non-invasive low toxicity and side effects, significantly inhibiting a plurality of tumors, influencing the intracellular superoxide radical content, and promoting cell autophagy. The mechanism of action of the magnetic field is on the electron spin energy levels and consequently on free radical concentration. Additional magnetic field having frequency up to 100 MHz and intensity down to microTesla range can be also used to improve the antitumor efficacy in combination with the static as well as the extremely low frequency electromagnetic field (1-300 Hz) influencing the spin hyperfine resonance. A combination method is also provided of a power-frequency electromagnetic field generating device and a platinum-based medicine.
The three fruits of triphala (Terminalia chebula, Emblica officinalis and Terminalia bellerica) will be bought in powder form from an herbal drug vendor. A mixture will be made by combining equal proportion of all these three powders in distilled water. This will then be boiled till the volume reduces to 1/8th part of the initial volume. A sweetener will be added to the decoction followed by filtering using a white muslin cloth and then storing in a sterile amber-coloured glass bottle in a refrigerator. The decoction obtained will be subjected to dilution to obtain 0.6% concentration. This will then be used to impregnate the marketed tooth wipes fabric. The triphala tooth wipes will be cut, folded individually, and then packed. Each pack will contain 16 wipes.
Oral pathogens can produce volatile sulfur compounds (VSCs), which is the main reason for halitosis and indicates the risk of periodontitis. High-sensitivity detection of exhaled VSCs is urgently desired for promoting the point-of-care testing (POCT) of halitosis and screening of periodontitis. However, current detection methods often require bulky and costly instruments, as well as professional training, making them impractical for widespread detection. Here, a structural color hydrogel for naked-eye detection of exhaled VSCs is presented. VSCs can reduce disulfide bonds within the network, leading to expansion of the hydrogel and thus change of the structural color. A linear detection range of 0-1 ppm with a detection limit of 61 ppb can be achieved, covering the typical VSC concentration in the breath of patients with periodontitis. Furthermore, visual and in situ monitoring of Porphyromonas gingivalis responsible for periodontitis can be realized. By integrating the hydrogels into a sensor array, the oral health conditions of patients with halitosis can be evaluated and distinguished, offering risk assessment of periodontitis. Combined with a smartphone capable of color analysis, POCT of VSCs can be achieved, providing an approach for the monitoring of halitosis and screening of periodontitis.
Sarcopenia is a musculoskeletal disorder related to muscle mass and function; as the worldwide population ages, its growing prevalence means a decline in quality of life and an increased burden for public health systems. As sarcopenia is a reversible condition, its early diagnosis is of utmost importance. Consensus definitions and diagnosis protocols for sarcopenia have been evolving for a long time, and the identification of molecular pathways subjacent to sarcopenia is a growing research area. The use of liquid biopsies to identify circulating molecules does not provide information about specific regulatory pathways or biomarkers in relevant tissue, and the use of skeletal muscle biopsies from older people has many limitations. Complementary tools are therefore necessary to advance the knowledge of relevant molecular aspects. The development of experimental models, such as animal, cellular, or bioengineered tissue, together with knock-in or knock-out strategies, could therefore be of great interest. This narrative review will explore experimental models of healthy muscle and aged muscle cells as a tool for research on sarcopenia. We will summarize the literature and present relevant experimental models in terms of their advantages and disadvantages. All of the presented approaches could potentially contribute to the accurate and early diagnosis, follow-up, and possible treatment of sarcopenia.
A prospective randomized controlled study was undertaken of patients with solid pancreatic mass lesions who were referred for EUS. Total 120 patients were randomized with 1:1 ratio into undergo CEH-EUS-guided FNB or conventional EUS-guided FNB with fanning technique. At the time of the procedure, the endoscopy nurse opened an envelope containing computer-generated randomization assignments for the study patients. All procedures were performed by a linear array echoendoscope (Olympus UCT260; Olympus, Tokyo, Japan). Procedures were performed under conscious sedation with patients in the left lateral decubitus position.

In CEH-EUS-guided FNB group, needle puncture directly to the enhancing area 15-20 times without passing to the non-enhancing area was performed. In conventional-EUS-guided FNB with fanning technique group, the needle was positioned at four different areas within the mass and then moved back and forth four times in each area to procure tissue (4 × 4). After each pass, the needle is removed and the stylet will be introduced into the needle to extrude any aspirated material on a glass slide for inspection of the presence of a macroscopic visible core (MVC). The total length of the MVC will be measured before placement into a formalin bottle. EUS-FNB is completed if the obtained MVC is longer than 4mm and deemed adequate by endoscopist. If the obtained MVC is \< 4mm, the procedure is repeated until a MVC of ≥ 4mm is obtained and deemed adequate by endoscopist. A maximum of 7 passes is allowed.
Education Webinar session topics are the same that are covered in the intervention arm without telephone interaction/support and skills building components. Each session is 30-minutes. Each participant receives a Spouse Workbook with information and activities.
The invention relates to a medicine for livestock and poultry. 10-60 parts of Jasminum Amplexicaule, 10-40 parts of ovate leaf holly bark, 5-40 parts of herba hyperici japonici and 5-30 parts of pittosporum clypearia. The preferable mixture ratio is as follows: 30 parts of Jasminum Amplexicaule, 20 parts of cortex Ilicis Rotundae, 25 parts of herba Hyperici Japonici and 15 parts of Pithecellobium clypearia. The livestock and poultry comprise pigs, cattle or chickens and the like. Compared with the prior art, the invention has the following advantages: (1) the invention has the advantages of safety, natural traditional Chinese medicine as raw material, no toxic and side effect, no residue and no food-borne antibiotic drug resistance. (2) The composition has remarkable curative effect, the antidiarrheal effect is superior to that of berberine hydrochloride, the total effective rate of the preferable formula can reach 95.5 percent, and the components of the composition have synergistic effect in treating the livestock diarrhea.
As a global health concern, cirrhosis contributes significantly to morbidity and mortality. This prospective cohort study aimed to investigate the association between dietary acid load (DAL) and cirrhosis-related mortality. Present study was conducted on 121 patients with newly diagnosed cirrhosis who were followed up for 48 months. Anthropometric measures, nutritional status and dietary intakes were assessed and DAL was estimated based on potential renal acid load (PRAL) and net endogenous acid production (NEAP) scores. Crude and multivariable-adjusted hazard ratios (HR) with 95% confidence intervals (CI) were estimated using Cox proportional hazard analyses. Participants in the high PRAL and NEAP scores had significantly higher intakes of grains and lower intakes of fruits and vegetables. Also, the intake of dairy products and legumes, nuts and seeds decreased significantly with increasing NEAP score. After adjustment of all the confounders, the risk of mortality in the second and third tertiles of PRAL was 5.9 times and 10.97 higher than those in the first tertile, respectively (P trend: 0.006). Similarly, comparing the risk of mortality in the second and third tertiles with the first tertile of NEAP showed a 4.46-fold and 12.3-fold increased risk, respectively (P trend: 0.010). Our findings suggested that DAL was significantly associated with cirrhosis-related mortality and highlight the need for further research to understand the underlying mechanisms and establish optimal DAL levels in cirrhotic patients.
Late-onset Gaucher disease (GD) present a unique set of challenges compared to their early-onset counterparts. Symptoms may not appear until adulthood, leading to delayed diagnosis and treatment. This delay can result in irreversible damage to affected tissues and organs, such as the liver, spleen, and central nervous system. Additionally, many late-onset GD are underdiagnosed or misdiagnosed due to their rarity and the variability of symptoms. This study is divided into two phases. In the first phase, patients with hepatosplenomegaly of unknown etiology will be initially screened using an electronic medical record database, and in the second phase, laboratory analysis of biomarkers, including Dry blood spot (DBS) for GBA1 enzyme activity, plasma Lyso-GB1 levels and GBA1 gene sequencing, will be performed. Acid sphingomyelinase deficiency (ASMD) is another lysosomal storage disorder that shares symptoms with GD. Consistent with the above screening strategy for GD patients in two phases (DBS for ASM enzyme activity, plasma Lyso-SM levels and ASM gene sequencing). This study will involve 2,000 candidates from electronic healthcare databases, 240 patients from outpatient clinics, and a cohort of 6 GD1/GD3 patients as controls. In conclusion, initial screening for late-onset GD and ASMD can provide patients with treatment opportunities that can improve outcomes for those affected by these rare diseases.